InMode Lowers FY25 Revenue Guidance

InMode (INMD) reported preliminary Q2 revenue of $95.4-$95.5 million but significantly lowered its full-year 2025 revenue guidance to $365-$375 million from the prior $395-$405 million range. The company attributed this downward revision to continued market weakness and persistent uncertainty surrounding the U.S. economic outlook, resulting in a 6% decline in INMD shares during pre-market trading.

Analysis

InMode (INMD) has issued a material downward revision to its full-year 2025 revenue guidance, lowering the forecast to a range of $365-$375 million from a prior $395-$405 million. Management explicitly attributes this reduction to persistent market weakness and uncertainty in the U.S. economic outlook, suggesting that macroeconomic headwinds are directly impacting demand for its products. This negative forward-looking statement has overshadowed the company's preliminary second-quarter results, which include stable revenue of $95.4-$95.5 million and a strong non-GAAP gross margin between 79% and 80%. The market's reaction was immediate and negative, with shares falling 6% in pre-market trading, indicating that investors are prioritizing the weakened growth outlook over the resilient current-quarter profitability. The full earnings release on July 30, 2025, will be a critical catalyst for investors seeking more granular detail on the severity and expected duration of these headwinds.

Key Decisions for Investors

• Investors should re-evaluate valuation models for INMD to reflect the significantly lower full-year revenue forecast, which signals a material deceleration in growth.
• It is crucial to monitor the July 30th earnings call for management's specific commentary on the drivers of 'market weakness' and any updated outlook for the second half of the year.
• Consider this announcement a potential bellwether for the broader medical aesthetics industry, as the stated macroeconomic headwinds are unlikely to be isolated to InMode.
• Despite the negative top-line revision, the high preliminary non-GAAP gross margin of 79-80% suggests operational strength and should be factored into any risk-reward analysis of the stock.